Issue 6/2022
Content (9 Articles)
Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms
Kévin Chemello, Dirk J. Blom, A. David Marais, Gilles Lambert, Valentin Blanchard
Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia
Antonio Gallo, Reed Mszar, Marcio Hiroshi Miname
Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?
Erin Jacob, Robert A. Hegele
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?
Rodrigo Alonso, Rosa Argüeso, Pilar Álvarez-Baños, Ovidio Muñiz-Grijalvo, Jose Luis Diaz-Diaz, Pedro Mata
Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies
Alexander P. Hoffmann, Michael C. Honigberg
Next Generation Risk Markers in Preventive Cardio-oncology
Morgan Lamberg, Andrea Rossman, Alexandra Bennett, Sabrina Painter, Rachel Goodman, James MacLeod, Ragasnehith Maddula, David Rayan, Krishna Doshi, Alexander Bick, Simone Bailey, Sherry-Ann Brown
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm
Feng Gao, Faisal Rahman
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?
Sarah Jackson, Ana Creo, Seema Kumar
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis
Marion Mussbacher, Klaudia Schossleitner, Julia B. Kral-Pointner, Manuel Salzmann, Astrid Schrammel, Johannes A. Schmid